Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04829227 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Sofwave Treatment to Lift Lax Skin
A Phase 3 study of Skin Laxity, sponsored by Sofwave Medical.
- Completed
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
- 4
- Study locations
NCT04829227 is a Phase 3 study of Skin Laxity that has completed, run by Sofwave Medical. The registered enrollment target is 45 participants, below the 186-participant average among 10 other Skin Laxity trials with a reported enrollment target (76% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT04829227, a Phase 3 study of Skin Laxity, has completed, sponsored by Sofwave Medical.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
- 4
- Study locations
Study Summary
Open-label, non-randomized 2 arms prospective, multi-center, self-controlled clinical study with masked evaluation.
Conditions Studied
Interventions
- DEVICE Sofwave
Study Locations (4)
Tennessee
- The Practice of Brian S. Biesman, MD - Nashville
- Tennessee Clinical Research Center - Nashville
New Jersey
- SLSS, a Division of Schweiger Dermatology Group Research Office - Hackensack
Virginia
- McDaniel Institute of Aging Research - Virginia Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2020-01-10 |
| Est. Completion | 2021-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04829227
The ClinicalTrials.gov registry entry for NCT04829227 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 10 other Skin Laxity trials with a reported enrollment target (76% lower). The listed sponsor is Sofwave Medical, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Skin Laxity appearing as the primary indexed condition, and to 1 intervention - of which Sofwave is the first listed.
NCT04829227 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Tennessee, New Jersey, Virginia.
Frequently Asked Questions
What is clinical trial NCT04829227 about?
NCT04829227 is a clinical study titled "Safety and Efficacy of Sofwave Treatment to Lift Lax Skin". Open-label, non-randomized 2 arms prospective, multi-center, self-controlled clinical study with masked evaluation.
What is the current status of trial NCT04829227?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2020-01-10. Estimated completion is 2021-12-31.
What conditions does trial NCT04829227 study?
This clinical trial studies the following conditions: Skin Laxity.
What interventions are being tested in trial NCT04829227?
The interventions under investigation include: Sofwave (DEVICE).
Who is sponsoring clinical trial NCT04829227?
This trial is sponsored by Sofwave Medical, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04829227 being conducted?
This trial has 4 study locations across New Jersey, Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Laxity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging
RECRUITING · NA
-
An Evaluation of the Erchonia Laser As a Non-Invasive Treatment to Improve the Appearance of Skin Laxity
RECRUITING · NA
-
Evaluation of Fractional Ablative Laser Treatment for Skin Conditions
RECRUITING · NA
-
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
RECRUITING
-
AV-23-001 AVAVA MIRIA Pilot Study
ACTIVE NOT RECRUITING · NA
-
Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.